Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2

Interventions

pembrolizumab 610Carboplatin 376Paclitaxel 283Cisplatin 269Gemcitabine 256Pemetrexed 195Bevacizumab 191Nivolumab 190Docetaxel 190Injections 169Cyclophosphamide 148atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 129Fulvestrant 115durvalumab 114130-nm albumin-bound paclitaxel 111fludarabine 102Cetuximab 101Leucovorin 97Rituximab 96venetoclax 90Lenalidomide 84Prednisone 79enzalutamide 78Azacitidine 76Irinotecan 74Ipilimumab 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × azeliragon × 1 year × Clear all
NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed
33 enrolled
CNS

Glioblastoma

NCT05986851 2026-03-31

Azeliragon in MGMT Unmethylated Glioblastoma

Cantex Pharmaceuticals

Phase 2 Active not recruiting
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡